

NONVALENT HPV VACCINE: KEY POINTS FOR IMMUNISATION PROVIDERS


NEW VACCINE

Same manufacturing as 4vHPV but with addition of virus like particles against the next 5 most common HPV types that cause cervical cancer.

97%
EFFECTIVE

HIGHLY EFFECTIVE

Highly effective against added types [31 / 33 / 45 / 52 / 58] and antibodies as good as against [6 / 11 / 16 / 18].



270
MILLION
VACCINATIONS
GLOBALLY

USED GLOBALLY

HPV vaccines are safe and endorsed by World Health Organization (WHO). Used for over a decade globally with over 270 million doses.

ADVERSE REACTIONS

Most common adverse event is injection site reaction, contains 2x adjuvant of 4vHPV.

14 years
& under



15 years
& over



VACCINE SCHEDULE

Like all HPV vaccines, can now be used as two doses if dose 1 given at age 14 or under. Immunocompromised children need three doses even if 14 or under.

IMPORTANT INFORMATION

Revaccination if previously vaccinated with 4vHPV or 2vHPV is **not** routinely recommended:

- Most protection provided by protection against 16/18 already
- Estimated that 50% of HPV infection that will ever cause cervical cancer has been acquired by age 20 and 75% by age 30
- Lower antibody levels against additional types if previously vaccinated: clinical significance is unknown
- Possibly higher occurrence of injection site reactions
- Screening remains the most important cervical prevention strategy in sexually active women.



VACCINE COURSE

HPV vaccines are interchangeable if a course is incomplete.

If a different vaccine is used for one or more doses, clinical protection against types not included in every vaccine dose may be reduced.